Embecta (NASDAQ:EMBC) Upgraded by Wall Street Zen to Strong-Buy Rating

Embecta (NASDAQ:EMBC) was upgraded by equities researchers at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

A number of other analysts have also recently weighed in on EMBC. Weiss Ratings reiterated a “hold (c-)” rating on shares of Embecta in a research report on Wednesday, October 8th. Zacks Research lowered Embecta from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Finally, BTIG Research reiterated a “buy” rating on shares of Embecta in a research note on Tuesday, November 25th. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $18.50.

Embecta Stock Performance

Shares of NASDAQ:EMBC opened at $12.01 on Friday. The company’s fifty day moving average is $13.06 and its two-hundred day moving average is $12.60. Embecta has a 1-year low of $9.20 and a 1-year high of $21.23. The stock has a market capitalization of $711.11 million, a price-to-earnings ratio of 7.37 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Tuesday, November 25th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.46 by $0.04. The business had revenue of $263.30 million during the quarter, compared to analyst estimates of $265.66 million. Embecta had a net margin of 8.83% and a negative return on equity of 24.62%. The company’s quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.45 EPS. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts expect that Embecta will post 2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Embecta

Institutional investors and hedge funds have recently bought and sold shares of the stock. Comerica Bank boosted its holdings in shares of Embecta by 65.7% in the first quarter. Comerica Bank now owns 50,641 shares of the company’s stock valued at $646,000 after acquiring an additional 20,079 shares in the last quarter. American Century Companies Inc. lifted its position in Embecta by 36.3% in the second quarter. American Century Companies Inc. now owns 5,195,948 shares of the company’s stock worth $50,349,000 after purchasing an additional 1,382,537 shares during the period. Raymond James Financial Inc. boosted its stake in Embecta by 2.1% during the 1st quarter. Raymond James Financial Inc. now owns 326,156 shares of the company’s stock valued at $4,158,000 after purchasing an additional 6,640 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Embecta by 103.6% during the 2nd quarter. Squarepoint Ops LLC now owns 403,412 shares of the company’s stock valued at $3,909,000 after purchasing an additional 205,311 shares during the period. Finally, State of Alaska Department of Revenue raised its stake in shares of Embecta by 15.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 401,112 shares of the company’s stock worth $3,885,000 after buying an additional 52,566 shares in the last quarter. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.